Description
RNA splicing regulates prostate cancer progression to hormone therapy resistant neuroendocrine tumors
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02018-04-01$699,975
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2018-04-01(start date) | $699,975 | — | RNA splicing regulates prostate cancer progression to hormone therapy resistant neuroendocrine tumors |
Related records · 2
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2024-2025-Q3-00079 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Investigator-Initiated Research | $967,726 | FY2025 |
| 236-2021-2022-Q3-00666 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Investigator-Initiated Research | $910,350 | FY2022 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2017-2018-Q4-00122 · retrieved 2026-11-14.